TROBIX BIO LTD
General Data
Reg Number
515823276
Sector
Biomed
Established
2018
No. of Employees
10
Stage
Initial Revenues
Additional Funding
1
Description
Trobix Bio is developing orally available phage-based therapeutic candidates that target and reprogram microbiome bacteria using CRISPR. Lead products TBX201 and TBX301 are advancing preclinical development to treat life-threatening gastrointestinal side
Technology
TBX™ Technology combines proprietary molecular engineering and computational algorithms tools to developed CRISPR-based synthetic phages.
Leveraging their GOTraP™ direct evolution technology by integrating structural protein analysis, machine learning and AI algorithms, we optimize synthetic phages for precision delivery of DNA payloads to target bacteria.
They create customized potent CRISPR-based payloads by converging our ActiSense™ in-vivo selection technology with synthetic biology tools to control bacterial traits.
Targeted Customers
Human therapeutics, Animal health & Farming, Food safety and Consumer health markets.
Management personnel
Adi Elkeles - CEO & Co-Founder
Udi Qimron - CTO
Chanan Morris - CFO
Winning details
Route name
Winning year
R&D Program second/third year request for Entitled Growth Corporate
R&D Program second/third year request for Entitled Growth Corporate
2023